Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China

The Lancet 2026

View at publisher
Authors: S Lu, Baogang Liu, Yi Luo, L G Sun, Lin Wu, Zhengxiang Han, Yun Fan, Y W Zhao, Xingya Li, Xu H, Xiangjiao Meng, Ying Liu
+46 more Zhiye Zhang, Hui Luo, X F Ma, X F Ma, Q Shi, Zhongmin Zhang, Runxiang Yang, Pingli Wang, P Pan, Xiaohong Ai, J Y Li, Xingxiang Pu, Z Wang, Jian Fang, M He, Yong He, S Guo, J Y Li, Hongbiao Wang, Junqiang Zhang, Qian Chu, Xin Liu, Shenpeng Ying, Hongcheng Wu, Hongmei Sun, Y. Ji, Ming Zhou, Chao Cao, Ke Tang, Zhengguo Li, D H Li, Zhihong Zhang, J Y Li, Jianya Zhou, Hongzhong Yang, Yingying Du, Hui Yang, Jian Shi, Chen H, Zhiwei Chen, Wenting Li, Dongmei Lu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Y. Xia
DOI: 10.1016/s0140-6736(26)00966-9
Cited by: 7
References: 22

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10548
Pages
2620–2629
Publication date
31 May 2026
Language
EN